Renal

Localized

T1b or greater (has not spread beyond the kidney)

IRB#16576 Atezolizumab vs placebo as adjuvant therapy following nephrectomy

IRB#16300 Merck 3475

No Prior Systemic Therapy

Metastasectomy Candidate

IRB#9241 Pazopanib vs. Placebo in Patients with mRCC

Cytoreductive Nephrectomy Candidate

No trials Currently Available

IRB# 11283 A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone (Including a Lead-In Phase IB Dose-Escalation Portion) In Patients With Advanced Or Metastatic Renal Cell Carcinoma.

IRB# 16085 S1500 – Cabozantinib, Crizotinib, Savolitinib and sunitinib

Non- Clear Cell

Metastatic/advanced

Prior Systemic Therapy

No Trials Currently Available

No Trials Currently Available

T1b or greater (has not spread beyond the kidney)

IRB#16576 Atezolizumab vs placebo as adjuvant therapy following nephrectomy

IRB#16300 Merck 3475

No Prior Systemic Therapy

Metastasectomy Candidate

IRB#9241 Pazopanib vs. Placebo in Patients with mRCC

Cytoreductive Nephrectomy Candidate

No trials Currently Available

IRB# 11283 A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone (Including a Lead-In Phase IB Dose-Escalation Portion) In Patients With Advanced Or Metastatic Renal Cell Carcinoma.

IRB# 16085 S1500 – Cabozantinib, Crizotinib, Savolitinib and sunitinib

www.ohsu.edu/cancer